ヘマブ・セラピューティクス・ホールディングス
Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.80 | $0 | -$23M |
| 2026 Q1 | -0.51 | $0 | -$22M |